Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy.
van de Ven R, Reurs AW, Wijnands PGJTB, van Wetering S, Kruisbeek AM, Hooijberg E, Scheffer GL, Scheper RJ, de Gruijl TD. van de Ven R, et al. Among authors: kruisbeek am. Cancer Immunol Immunother. 2012 Feb;61(2):181-191. doi: 10.1007/s00262-011-1039-x. Epub 2011 Aug 27. Cancer Immunol Immunother. 2012. PMID: 21874304 Free PMC article.
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.
van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD. van de Loosdrecht AA, et al. Among authors: kruisbeek am. Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23. Cancer Immunol Immunother. 2018. PMID: 30039426 Free PMC article. Clinical Trial.
Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.
van den Ancker W, Wijnands PG, Ruben JM, Westers TM, Punt B, Bachas C, Ravenshorst N, van Wetering S, Kruisbeek AM, Bontkes HJ, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD. van den Ancker W, et al. Among authors: kruisbeek am. Immunotherapy. 2013 Nov;5(11):1183-90. doi: 10.2217/imt.13.125. Immunotherapy. 2013. PMID: 24188673 Clinical Trial.
DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.
Leaf RK, Stroopinsky D, Pyzer AR, Kruisbeek AM, van Wetering S, Washington A, Ephraim A, Cole L, Morin A, Jain S, Nahas MR, Apel A, Arnason J, Hamdan A, Rosenblatt J, Avigan D. Leaf RK, et al. Among authors: kruisbeek am. J Immunother. 2017 Nov/Dec;40(9):315-322. doi: 10.1097/CJI.0000000000000185. J Immunother. 2017. PMID: 28961609
Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade.
Zuo H, van Lierop MC, Kaspers J, Bos R, Reurs A, Sarkar S, Konry T, Kamermans A, Kooij G, de Vries HE, de Gruijl TD, Karlsson-Parra A, Manting EH, Kruisbeek AM, Singh SK. Zuo H, et al. Among authors: kruisbeek am. Cells. 2021 Nov 19;10(11):3233. doi: 10.3390/cells10113233. Cells. 2021. PMID: 34831455 Free PMC article.
CD8+ T cell tolerance and cancer immunotherapy.
De Visser KE, Schumacher TN, Kruisbeek AM. De Visser KE, et al. Among authors: kruisbeek am. J Immunother. 2003 Jan-Feb;26(1):1-11. doi: 10.1097/00002371-200301000-00001. J Immunother. 2003. PMID: 12514424 Review.
147 results